• Vaccine Name: ΔureC hly+ rBCG
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Vaccine Ontology ID: VO_0000606
• Type: Live, attenuated vaccine
• Status: Research
• Preparation: In order to generate a live vaccine that provides improved protection against M. tuberculosis, BCG was equipped with the membrane-perforating Hly of L. monocytogenes (hly+ rBCG). To improve the pH milieu for Hly activity, a ΔureC hly+ rBCG strain that lacked ureC activity was constructed (Grode et al., 2005).
• Immunization Route: Intramuscular injection (i.m.)

Cattle Response

• Vaccination Protocol: Mice were immunized i.v. with 10^6 CFU of BCG strains (Grode et al., 2005).
• Challenge Protocol: At 120 days after vaccination, animals were aerosol challenged with 100–200 CFU of M. tuberculosis H37Rv or Beijing/W per lung using an aerosol chamber (Glas-Col) (Grode et al., 2005).
• Efficacy: The ΔureC hly+ rBCG vaccine strain induced significantly more efficacious in inducing protective immunity against 2 different M. tuberculosis strains, the laboratory strain H37Rv and a clinical isolate of the Beijing/W genotype family, in a mouse model, than parental BCG (Grode et al., 2005). The ΔureC hly+ rBCG vaccine provided even more efficient protection than the hly+ rBCG vaccine strain.